共 50 条
Early Target Attainment With Continuous Infusion Meropenem and Piperacillin/Tazobactam and Utilization of Therapeutic Drug Monitoring in Critically Ill Patients: A Retrospective Cohort Study From 2017 to 2020
被引:3
|作者:
Drager, Sarah
[1
,2
]
von Rotz, Matthias
[3
]
Labhardt, Niklaus D.
[3
,4
,5
]
Siegemund, Martin
[2
,6
]
Rentsch, Katharina M.
[7
]
Osthoff, Michael
[1
,2
]
Franzeck, Fabian C.
[5
,8
]
机构:
[1] Univ Hosp Basel, Div Internal Med, Basel, Switzerland
[2] Univ Basel, Dept Clin Res, Basel, Switzerland
[3] Univ Hosp Basel, Div Infect Dis & Hosp Epidemiol, Basel, Switzerland
[4] Swiss Trop & Publ Hlth Inst, Dept Med, Clin Res Unit, Allschwil, Switzerland
[5] Univ Basel, Basel, Switzerland
[6] Univ Hosp Basel, Dept Acute Med, Intens Care Unit, Basel, Switzerland
[7] Univ Hosp Basel, Dept Lab Med, Basel, Switzerland
[8] Univ Hosp Basel, Dept Res & Analyt Serv, Basel, Switzerland
来源:
关键词:
continuous infusion;
critically ill patients;
meropenem;
therapeutic drug monitoring;
BETA-LACTAM ANTIBIOTICS;
AUGMENTED RENAL CLEARANCE;
INTERMITTENT BOLUS;
PHARMACODYNAMICS;
INFECTIONS;
SEPSIS;
FLUCLOXACILLIN;
METAANALYSIS;
CHALLENGES;
TISSUE;
D O I:
10.1093/ofid/ofad143
中图分类号:
R392 [医学免疫学];
Q939.91 [免疫学];
学科分类号:
100102 ;
摘要:
Background We analyzed the attainment of early pharmacological targets of continuous infusion meropenem and piperacillin/tazobactam and the use and effect of a real-time therapeutic drug monitoring (TDM) program on subsequent dosing and target attainment in patients who are critically ill. Methods This was a single-center, retrospective study among patients hospitalized in the intensive care unit in a Swiss tertiary care hospital from 2017 to 2020. The primary outcome was target attainment [100% tT (>= 4xECOFF (Pseudomonas aeruginosa))] of continuous infusion meropenem and piperacillin/tazobactam within 72 hours after initiation of treatment. Results A total of 234 patients were included. Median first meropenem (n = 186 of 234) and piperacillin (n = 48 of 234) concentration was 21 mg/L (interquartile range [IQR], 15.6-28.6) and 100.7 mg/L (IQR, 64.0-160.2), respectively. Pharmacological target was attained in 95.7% (95% confidence interval [CI], 91.7-98.1) of patients receiving meropenem and 77.0% (95% CI, 62.7-87.9) treated with piperacillin/tazobactam. In the univariable and multivariable logistic regression, body weight and estimated glomerular filtration rate were negatively associated with target attainment. Subsequently, meropenem dosage was decreased or stopped in 35 of 186 (18.8%) and 89 of 186 (47.9%) patients, respectively, and increased in 2 of 186 (1.1%) patients. Conclusions Continuous infusion meropenem and piperacillin/tazobactam yielded excellent and moderate early pharmacological target attainment in critically ill patients, respectively. The TDM was mainly used to decrease meropenem dosage. In this observational study in critically ill patients, continuous infusion meropenem and piperacillin/tazobactam yielded excellent and moderate early pharmacological target attainment measuring antibiotic concentration in plasma.
引用
收藏
页数:10
相关论文